Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I

YIC-IR

	Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I
	Yuankai Shi 1; Jianying Zhou 2; Yanqiu Zhao 3; Bo Zhu 4; Liangming Zhang 5; Xingya Li 3; Jian Fang 6; Jianhua Shi 7; Zhixiang Zhuang 8; Sheng Yang 1; Donglin Wang 9; Huiqing Yu 9; Longzhen Zhang 10; Rongsheng Zheng 11; Michael Greco 12; Tingting Wang 13
发表期刊	BMC MEDICINE
ISSN	1741-7015
	2023
卷号	21 期号:1
英文摘要	Rezivertinib (BPI-7711) is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). This phase IIa study was part of a phase I EGFR mutated non-small cell lung cancer (NSCLC).
语种	英语
文献类型	期刊论文
条目标识符	http://ir.yic.ac.cn/handle/133337/34555
专题	中国科学院烟台海岸带研究所
作者单位	1.中国医学科学院北京协和医学院 2.浙江大学 3.郑州大学 4.Institute of Cancer, Xinqiao Hospital, Third Military Medical University 5.中国科学院烟台海岸带研究所 6.Beijing Cancer Hospital 7.Linyi Cancer Hospital 8.苏州大学 9.重庆大学 10.徐州医科大学 11.蚌埠医学院 12.Beta Pharma Inc. 13.Beta Pharma Co., Ltd
推荐引用方式 GB/T 7714	Yuankai Shi,Jianying Zhou,Yanqiu Zhao,et al. Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I[J]. BMC MEDICINE,2023,21(1).
APA	Yuankai Shi.,Jianying Zhou.,Yanqiu Zhao.,Bo Zhu.,Liangming Zhang.,...&Tingting Wang.(2023).Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I.BMC MEDICINE,21(1).
MLA	Yuankai Shi,et al."Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I".BMC MEDICINE 21.1(2023).